Josef Kredba, country manager Czech Republic at G.L. Pharma, an Austrian pharmaceutical company, explains how the company has returned to growth in the challenging Czech generics market and shares his thoughts on market access and pricing conditions for both innovative and generic products.
On the one hand, authorities recognize the role of generics in making medicines more available and affordable for the healthcare system by introducing healthy competition. On the other hand, the state has not been successful in the price management of innovative products
